AstraZeneca Selumetinib and Tagrisso are recommended and approved by the EU

CompileKe Ke

On April 26, AstraZeneca announced that its drug selumetinib, developed in cooperation with Merck & Co.

On the same day, AstraZeneca also announced that Tagrisso (osimertinib) has also been recommended for marketing in the European Union for the adjuvant treatment of early (IB, II and IIIA) epidermal growth factor receptor mutations (EGFRm) non-small cell lung cancer (NSCLC) adults Patients, these patients still have treatment intentions after the tumor is completely removed.

Selumetinib

AstraZeneca and Merck introduced that the European Medicines Agency's (EMA) Committee for Human Medicines (CHMP) published the results of the Phase II clinical trial SPRINT Stratum 1 sponsored by the National Cancer Institute (NCI) Cancer Treatment Evaluation Project (CTEP) Positive opinions.

The Phase 1/2 clinical trial SPRINT Stratum 1 aims to evaluate the objective response rate and the impact of patient reports and functional outcome analysis on children with NF1-related inoperable PNs treated with selumetinib monotherapy.

Selumetinib is an inhibitor of mitogen-activated protein kinase kinase 1 and 2 (MEK1/2).

Selumetinib was approved in the United States in April 2020 for the treatment of pediatric patients with NF1 and symptomatic, inoperable PN.

Tagrisso

According to AstraZeneca, CHMP gave a positive opinion on the results of the Phase III clinical trial ADAURA.

ADAURA is a randomized, double-blind, global, placebo-controlled phase three clinical trial used for adjuvant therapy in 682 patients with stage IB, II, and IIIA EGFRm NSCLC.

Tagrisso (osimertinib) is a third-generation irreversible EGFR-TKI with clinical activity against central nervous system metastasis.

Currently, Tagrisso's Phase III trials of locally advanced unresectable group (LAURA), neoadjuvant resectable group (Neoadura) and combination chemotherapy group (FLAURA2) are still ongoing.

Reference source:

1.

2.